These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29097503)

  • 1. Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.
    Capogrosso RF; Mantuano P; Uaesoontrachoon K; Cozzoli A; Giustino A; Dow T; Srinivassane S; Filipovic M; Bell C; Vandermeulen J; Massari AM; De Bellis M; Conte E; Pierno S; Camerino GM; Liantonio A; Nagaraju K; De Luca A
    FASEB J; 2018 Feb; 32(2):1025-1043. PubMed ID: 29097503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
    Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
    J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanical factors tune the sensitivity of mdx muscle to eccentric strength loss and its protection by antioxidant and calcium modulators.
    Lindsay A; Baumann CW; Rebbeck RT; Yuen SL; Southern WM; Hodges JS; Cornea RL; Thomas DD; Ervasti JM; Lowe DA
    Skelet Muscle; 2020 Feb; 10(1):3. PubMed ID: 32007101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rycal S48168 (ARM210) for
    Todd JJ; Lawal TA; Chrismer IC; Kokkinis A; Grunseich C; Jain MS; Waite MR; Biancavilla V; Pocock S; Brooks K; Mendoza CJ; Norato G; Cheung K; Riekhof W; Varma P; Colina-Prisco C; Emile-Backer M; Meilleur KG; Marks AR; Webb Y; Marcantonio EE; Foley AR; Bönnemann CG; Mohassel P
    EClinicalMedicine; 2024 Feb; 68():102433. PubMed ID: 38318125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term treatment with taurine prevents cardiac dysfunction in mdx mice.
    Mele A; Mantuano P; De Bellis M; Rana F; Sanarica F; Conte E; Morgese MG; Bove M; Rolland JF; Capogrosso RF; Pierno S; Camerino GM; Trabace L; De Luca A
    Transl Res; 2019 Feb; 204():82-99. PubMed ID: 30347179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoscale remodeling of ryanodine receptor cluster size underlies cerebral microvascular dysfunction in Duchenne muscular dystrophy.
    Pritchard HAT; Pires PW; Yamasaki E; Thakore P; Earley S
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):E9745-E9752. PubMed ID: 30181262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.
    Spurney CF; Sali A; Guerron AD; Iantorno M; Yu Q; Gordish-Dressman H; Rayavarapu S; van der Meulen J; Hoffman EP; Nagaraju K
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):87-95. PubMed ID: 21304057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAT-μUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice.
    Call JA; Ervasti JM; Lowe DA
    J Appl Physiol (1985); 2011 Jul; 111(1):200-5. PubMed ID: 21565990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy.
    Kayali R; Ku JM; Khitrov G; Jung ME; Prikhodko O; Bertoni C
    Hum Mol Genet; 2012 Sep; 21(18):4007-20. PubMed ID: 22692682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle.
    Bellinger AM; Reiken S; Carlson C; Mongillo M; Liu X; Rothman L; Matecki S; Lacampagne A; Marks AR
    Nat Med; 2009 Mar; 15(3):325-30. PubMed ID: 19198614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
    Xu DQ; Zhao L; Li SJ; Huang XF; Li CJ; Sun LX; Li XH; Zhang LY; Jiang ZZ
    Acta Pharmacol Sin; 2021 Jul; 42(7):1080-1089. PubMed ID: 32939036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.
    Spurney CF; Guerron AD; Yu Q; Sali A; van der Meulen JH; Hoffman EP; Nagaraju K
    BMC Cardiovasc Disord; 2011 May; 11():20. PubMed ID: 21575230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice.
    Altamirano F; Valladares D; Henríquez-Olguín C; Casas M; López JR; Allen PD; Jaimovich E
    PLoS One; 2013; 8(12):e81222. PubMed ID: 24349043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice.
    Sali A; Many GM; Gordish-Dressman H; van der Meulen JH; Phadke A; Spurney CF; Cnaan A; Hoffman EP; Nagaraju K
    PLoS One; 2013; 8(7):e66617. PubMed ID: 23843959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of hindlimb suspension on calcium-induced contraction characteristics in dystrophin-deficient animals.
    Litvinova KS; Shenkman BS
    J Gravit Physiol; 2007 Jul; 14(1):P91-2. PubMed ID: 18372714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.